1
|
Wade J, Petitpas KM, Dar W, Ali A, Radojevic JA, Lawlor MT, Hammond JA, Gluck J, Feingold AD, Jaiswal A, Ebcioglu Z, Einstein M, Morgan G, Emmanuel B, Ye X, Singh JU, Sotil EU, Swales C, Kent R, Richardson E, Cheema F, Serrano OK. Non-Lung Solid Organ Transplantation From SARS-CoV-2-Positive Donors to Uninfected Recipients. Transplant Proc 2023; 55:1793-1798. [PMID: 37487863 DOI: 10.1016/j.transproceed.2023.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Accepted: 06/23/2023] [Indexed: 07/26/2023]
Abstract
BACKGROUND There is a paucity of evidence on the risk of donor-recipient transmission of the SARS-CoV-2 in solid organ transplant recipients. Initial impressions suggest non-lung solid organs may be safely transplanted from SARS-CoV-2-positive donors without risk of viral transmission. METHODS We reviewed clinical results of transplants in which SARS-CoV-2-negative recipients received non-lung solid organs from SARS-CoV-2-positive donors at a single transplant center. No prisoners were used in this study, and participants were neither coerced nor paid. The manuscript was created in compliance with the Helsinki Congress and the Declaration of Istanbul. RESULTS Between June 2021 and January 2023, we transplanted 26 solid organs, including 13 kidneys, 8 livers, 3 hearts, and 1 simultaneous heart and kidney, from 23 SARS-CoV-2-positive donors into 25 SARS-CoV-2 negative recipients. Two of the recipients had a positive SARS-CoV-2 real-time polymerase chain reaction after transplantation, but otherwise, patients had no SARS-CoV-2-related complications, and all patients to date are alive with excellent allograft function. CONCLUSION Transplantation of non-lung solid organs from SARS-CoV-2-positive donors into uninfected recipients can be safely performed without adverse effects from SARS-CoV-2.
Collapse
Affiliation(s)
- Jason Wade
- Department of Surgery, Hartford Hospital, Hartford, Connecticut
| | | | - Wasim Dar
- Department of Surgery, Hartford Hospital, Hartford, Connecticut; Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Ayyaz Ali
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut
| | - Joseph A Radojevic
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Michael T Lawlor
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Jonathan A Hammond
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut
| | - Jason Gluck
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Andrew D Feingold
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Abhishek Jaiswal
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Center for Advanced Heart Failure and Pulmonary Vascular Disease, Hartford Hospital, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Zeynep Ebcioglu
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Michael Einstein
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Glyn Morgan
- Department of Surgery, Hartford Hospital, Hartford, Connecticut; Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Bishoy Emmanuel
- Department of Surgery, Hartford Hospital, Hartford, Connecticut; Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Xiaoyi Ye
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Joseph U Singh
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Eva U Sotil
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Colin Swales
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Rebecca Kent
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Elizabeth Richardson
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Faiqa Cheema
- Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut
| | - Oscar K Serrano
- Department of Surgery, Hartford Hospital, Hartford, Connecticut; Transplant & Comprehensive Liver Center, Hartford, Connecticut; Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut.
| |
Collapse
|
2
|
Rogers R, Bodziak K, Cheema F, Chobanian M, Ebcioglu Z, Gabardi S, Ghai S, Gilligan H, Gohh R, Goyal N, Kavalam G, Mehri B, Rodig N, Rossi A, Singh J, Wood E, Tan CS, Pavlakis M. Implementing a regional standardized BK polyomavirus screening protocol across eleven transplant centres. Transpl Int 2021; 34:2680-2685. [PMID: 34628685 DOI: 10.1111/tri.14134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/18/2021] [Accepted: 09/26/2021] [Indexed: 11/27/2022]
Abstract
BK polyomavirus (BKPyV) reactivation is regularly monitored after kidney transplant to prevent progression to BK associated nephropathy (BKAN). The New England BK Consortium, made up of 12 transplant centres in the northeastern United States, conducted a quality improvement project to examine adherence to an agreed upon protocol for BKPyV screening for kidney transplants performed in calendar years 2016-2017. In a total of 1047 kidney transplant recipients (KTR) from 11 transplant centres, 204 (19%) had BKPyV infection, defined as detection of BKPyV in plasma, with 41 (4%) KTR progressing to BKAN, defined by either evidence on biopsy tissues or as determined by treating nephrologists. BKPyV infection was treated with reduction of immune suppressants (RIS) in >70% of the patients in all but two centres. There was no graft loss because of BKAN during the two-year follow-up. There were nine cases of post-RIS acute rejection detected during this same period. Adherence to the protocol was low with 54% at 12 months and 38% at 24 months, reflecting challenges of managing transplant patients at all centres. The adherence rate was positively correlated to increased detection of BKPyV infection and was unexpectedly positively correlated to an increase in diagnosis of BKAN.
Collapse
Affiliation(s)
- Ralph Rogers
- Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - Kenneth Bodziak
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
| | - Faiqa Cheema
- Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT, USA
| | - Michael Chobanian
- Department of Transplantation Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
| | - Zeynep Ebcioglu
- Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT, USA
| | - Steven Gabardi
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Sandeep Ghai
- Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - Hannah Gilligan
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Reginald Gohh
- Division of Transplant Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - Nitender Goyal
- Department of Medicine, Tufts University School of Medicine, Boston, MA, USA
| | - George Kavalam
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Basma Mehri
- Division of Transplant Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - Nancy Rodig
- Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Ana Rossi
- Piedmont Transplant Institute, Atlanta, GA, USA
| | - Joseph Singh
- Department of Transplantation Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
| | - Emily Wood
- Maine Medical Center, Tufts University School of Medicine, Portland, ME, USA
| | - Chen Sabrina Tan
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Martha Pavlakis
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
3
|
Marti K, Rochon C, O'Sullivan DM, Ye X, Ebcioglu Z, Kainkaryam PP, Kuzaro H, Morgan G, Serrano OK, Singh J, Tremaglio J, Kutzler HL. Evaluation of a multimodal analgesic regimen on outcomes following laparoscopic living donor nephrectomy. Clin Transplant 2021; 35:e14311. [PMID: 33829561 DOI: 10.1111/ctr.14311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 03/24/2021] [Accepted: 04/01/2021] [Indexed: 11/29/2022]
Abstract
Postoperative pain is a significant source of morbidity in patients undergoing living donor nephrectomy (LDN) and a deterrent for candidates. We implemented a standardized multimodal analgesic regimen, which consists of pharmacist-led pre-procedure pain management education, a combination transversus abdominis plane and rectus sheath block performed by the regional anesthesia team, scheduled acetaminophen and gabapentin, and as-needed opioids. This single-center retrospective study evaluated outcomes between patients undergoing LDN who received a multimodal analgesic regimen and a historical cohort. The multimodal cohort had a significantly shorter length of stay (LOS) (days, mean ± SD: 1.8 ± 0.7 vs. 2.6 ± 0.8; p < .001) and a greater proportion who were discharged on postoperative day (POD) 1 (38.6% vs. 1.5%; p < .001). The total morphine milligram equivalents (MME) that patients received during hospitalization were significantly less in the multimodal cohort on POD 0-2. The outpatient MME prescribed through POD 60 was also significantly less in the multimodal cohort (median [IQR]; 180 [150-188] vs. 225 [150-300]; p < .001). The mean patient-reported pain score (PRPS) was significantly lower in the multimodal cohort on POD 0-2. The maximum PRPS was significantly lower on POD 0 (mean ± SD: 7 ± 2 vs. 8 ± 1, respectively; p = .02). This study suggests that our multimodal regimen significantly reduces LOS, PRPS, and opioid requirements and has the potential to improve the donation experience.
Collapse
Affiliation(s)
- Kristen Marti
- Department of Pharmacy Services, Hartford Hospital, Hartford, CT, USA
| | - Caroline Rochon
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | - David M O'Sullivan
- Department of Research Administration, Hartford HealthCare, Hartford, CT, USA
| | - Xiaoyi Ye
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | - Zeynep Ebcioglu
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | | | - Hillary Kuzaro
- Department of Pharmacy Services, Hartford Hospital, Hartford, CT, USA.,Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | - Glyn Morgan
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | - Oscar K Serrano
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | - Joseph Singh
- Department of Transplant, Hartford Hospital, Hartford, CT, USA
| | | | - Heather L Kutzler
- Department of Pharmacy Services, Hartford Hospital, Hartford, CT, USA.,Department of Transplant, Hartford Hospital, Hartford, CT, USA
| |
Collapse
|
4
|
Stamps H, Linder K, O'Sullivan DM, Serrano OK, Rochon C, Ebcioglu Z, Singh J, Ye X, Tremaglio J, Sheiner P, Cheema F, Kutzler HL. Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte-depleting induction. Transpl Infect Dis 2021; 23:e13573. [PMID: 33527728 DOI: 10.1111/tid.13573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 11/22/2020] [Accepted: 01/17/2021] [Indexed: 11/28/2022]
Abstract
Cytomegalovirus (CMV) is a significant cause of morbidity in kidney transplant recipients (KTR). Historically at our institution, KTR with low and intermediate CMV risk received 6 months of valganciclovir if they received lymphocyte depleting induction therapy. This study evaluates choice and duration of CMV prophylaxis based on donor (D) and recipient (R) CMV serostatus and the incidence of post-transplant CMV viremia in low (D-/R-) and intermediate (R+) risk KTR receiving lymphocyte-depleting induction therapy. A protocol utilizing valacyclovir for 3 months for D-/R- and valganciclovir for 3 months for R+ was evaluated. Adult D-/R- and R+ KTR receiving anti-thymocyte globulin, rabbit or alemtuzumab induction from 8/20/2016 to 9/30/2018 were evaluated through 1 year post-transplant. Patients were excluded if their CMV serostatus was D+/R-, received a multi-organ transplant, or received basiliximab. Seventy-seven subjects met the inclusion criteria: 25 D-/R- (4 historic group, 21 experimental group) and 52 R+ (31 historic, 21 experimental). No D-/R- patients experienced CMV viremia. Among the R+ historic and experimental groups, there was no significant difference in viremia incidence (35.5% vs 52.4%; P = .573). Of these cases, the peak viral load was similar between the groups (median [IQR], 67 [<200-444] vs <50 [<50-217]; P = .711), and there was no difference in the incidence of CMV syndrome (16.1% vs 14.3%; P = 1.000) or CMV related hospitalization (12.9% vs 14.3%; P = 1.000). No patient experienced tissue invasive disease. These results suggest limiting valganciclovir exposure may be possible in low and intermediate risk KTR receiving lymphocyte-depleting induction therapy with no apparent impact on CMV-related outcomes.
Collapse
Affiliation(s)
- Hillary Stamps
- Department of Pharmacy, Hartford Hospital, Hartford, CT, USA
| | - Kristin Linder
- Department of Pharmacy, Hartford Hospital, Hartford, CT, USA
| | - David M O'Sullivan
- Department of Research Administration, Hartford Healthcare, Hartford, CT, USA
| | - Oscar K Serrano
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Caroline Rochon
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Zeynep Ebcioglu
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Joseph Singh
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Xiaoyi Ye
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Joseph Tremaglio
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Patricia Sheiner
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Faiqa Cheema
- Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| | - Heather L Kutzler
- Department of Pharmacy, Hartford Hospital, Hartford, CT, USA.,Department of Transplant and Comprehensive Liver Center, Hartford Hospital, Hartford, CT, USA
| |
Collapse
|
5
|
Kutzler HL, Peters J, O’Sullivan DM, Williamson A, Cheema F, Ebcioglu Z, Einstein M, Rochon C, Ye X, Sheiner P, Singh JU, Sotil EU, Swales C, Serrano OK. Disparities in End-Organ Care for Hispanic Patients with Kidney and Liver Disease: Implications for Access to Transplantation. Curr Surg Rep 2020. [DOI: 10.1007/s40137-020-00248-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
6
|
Ebcioglu Z, Liu C, Shapiro R, Rana M, Salem F, Florman S, Huprikar S, Nair V. Belatacept Conversion in an HIV-Positive Kidney Transplant Recipient With Prolonged Delayed Graft Function. Am J Transplant 2016; 16:3278-3281. [PMID: 27328903 DOI: 10.1111/ajt.13923] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 05/15/2016] [Accepted: 06/12/2016] [Indexed: 01/25/2023]
Abstract
We report an HIV-positive renal transplant recipient with delayed graft function who was converted from tacrolimus to belatacept in an attempt to improve renal function. The patient had kidney biopsies at 4 and 8 weeks posttransplant that revealed acute tubular necrosis and mild fibrosis. After 14 weeks of delayed function, belatacept was initiated and tacrolimus was weaned off. Shortly after discontinuing tacrolimus, renal function began to improve. The patient was able to discontinue dialysis 21 weeks posttransplant. HIV viral load was undetectable at last follow-up. To our knowledge, this is the first report of belatacept use in a patient with HIV.
Collapse
Affiliation(s)
- Z Ebcioglu
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
| | - C Liu
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - R Shapiro
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - M Rana
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
| | - F Salem
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - S Florman
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - S Huprikar
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
| | - V Nair
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY. .,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
| |
Collapse
|
7
|
Nair V, Khaim R, El-Salem F, Kent R, Lerner S, Berger A, Miko L, Rollins B, Ebcioglu Z, Delaney V, Sehgal V, Menon M, Ames S, Benvenisty A, Wadhera V, Arvelakas A, Schiano T, Rana M, Huprikar S, Florman S, Shapiro R. Hepatitis C and Human Immunodeficiency Virus Kidney Transplantation: The Mount Sinai Experience. Clin Transpl 2015; 31:69-78. [PMID: 28514569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Mount Sinai Hospital in New York has a long history in the field of organ transplantation. The first kidney transplant at Mount Sinai was performed in 1967 by the late Dr. Lewis Burrows and the first laparoscopic donor nephrectomy in New York was performed at Mount Sinai in 1996. Over 3000 kidney transplantations have been performed at Mount Sinai. In the early 1990s, the first hepatitis C virus (HCV) positive patient at Mount Sinai underwent a kidney transplant and the first kidney transplant in a patient with human immunodeficiency virus (HIV) in New York was performed at Mount Sinai in 2001. In general, these patients have done well after renal transplantation, with outcomes similar to those seen in non-infected patients. This chapter will describe the evolution of immunosuppressive regimens in HCV positive and HIV positive patients, and will describe the outcomes of kidney transplantation in these patients. Given the favorable outcomes, it is reasonable to continue to offer renal transplantation as a treatment for end stage renal disease patients with HCV and/or HIV.
Collapse
Affiliation(s)
- Vinay Nair
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Rafael Khaim
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Fadi El-Salem
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Rebecca Kent
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Susan Lerner
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Amnon Berger
- Clinical Virology Unit and Department of Biochemistry and the Chanock Center for Virology, IMRIC, Hadassah Hebrew University Medical Center and Faculty of Medicine, Jerusalem, Israel
| | - Leandra Miko
- Pharmacy Department, The Mount Sinai Medical Center, New York, NY
| | - Brett Rollins
- Pharmacy Department, The Mount Sinai Medical Center, New York, NY
| | - Zeynep Ebcioglu
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Veronica Delaney
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Vinita Sehgal
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Madhav Menon
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Scott Ames
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Alan Benvenisty
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Vikram Wadhera
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Antonious Arvelakas
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Thomas Schiano
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Meena Rana
- Department of Medicine, Infectious Disease Division, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Shirish Huprikar
- Department of Medicine, Infectious Disease Division, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Sander Florman
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| | - Ron Shapiro
- Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY
| |
Collapse
|
8
|
Nair V, Sawinski D, Akalin E, Friedlander R, Ebcioglu Z, Sehgal V, Dinavahi R, Khaim R, Ames S, Lerner S, Murphy B, Bromberg JS, Heeger PS, Schröppel B. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant 2012; 26:E261-8. [PMID: 22686949 DOI: 10.1111/j.1399-0012.2012.01657.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Limited data exist on the effect of intravenous immunoglobulin (IVIg) on anti-HLA antibodies as determined by solid-phase assays. We reviewed our experience treating sensitized wait-listed kidney transplant recipients with IVIg as a method for desensitization and report our results utilizing Luminex single antigen (LSA) bead assay to quantify antibody reactivity (MFI). Fifteen patients with a cPRA > 40% received 2 g/kg IVIg per month for four months or until transplanted. LSA testing was performed before and after IVIg. Median MFI for anti-class I antibodies fell in 11 (73%) and increased in 4 (27%) patients after IVIg. Similar significant changes in MFI for anti-class II antibodies were observed in 10 patients (66%). Administration of IVIg was associated with a modest decrease in reactivity to both class I and II HLA antigens (median MFI change 493 and 1110, respectively; p < 0.0001) but did not significantly alter mean cPRA (85% before IVIg vs. 80% after IVIg; p = 0.1). Our data suggest a smaller effect of IVIg on HLA antibody reactivity than previously described, leading us to question how best to measure the efficacy of a desensitization protocol in current practice.
Collapse
Affiliation(s)
- Vinay Nair
- Division of Nephrology, Mount Sinai School of Medicine, New York, NY, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal V, Heeger P, Schroppel B, Murphy B. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10:2132-2141. [PMID: 20883548 PMCID: PMC4076707 DOI: 10.1111/j.1600-6143.2010.03210.x] [Citation(s) in RCA: 171] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Depletional induction therapies are routinely used to prevent acute rejection and improve transplant outcome. The effects of depleting agents on T-cell subsets and subsequent T-cell reconstitution are incompletely defined. We used flow cytometry to examine the effects of rabbit antithymocyte globulin (rATG) on the peripheral T-cell repertoire of pediatric and adult renal transplant recipients. We found that while rATG effectively depleted CD45RA+CD27+ naïve and CD45RO+CD27+ central memory CD4+ T cells, it had little effect on CD45RO+CD27- CD4+ effector memory or CD45RA+CD31-, CD45RO+CD27+ and CD45RO+CD27- CD8+ T cell subsets. When we performed a kinetic analysis of CD31+ recent thymic emigrants and CD45RA+/RO+ T cells, we found evidence for both thymopoiesis and homeostatic proliferation contributing to immune reconstitution. We additionally examined the impact of rATG on peripheral CD4+Foxp3+ T cells. We found that in adults, administration of rATG-induced peripheral expansion and new thymic emigration of T cells with a Treg phenotype, while CD4+Foxp3+ T cells of thymic origin predominated in children, providing the first evidence that rATG induces Treg in vivo. Collectively our data indicate that rATG alters the balance of regulatory to memory effector T cells posttransplant, providing an explanation for how it positively impacts transplant outcome.
Collapse
Affiliation(s)
- S. Gurkan
- Division of Pediatric Nephrology, UMDNJ, NJ
| | - Y. Luan
- Division of Nephrology, Mount Sinai School of Medicine, NY
| | - N. Dhillon
- Division of Nephrology, Mount Sinai School of Medicine, NY
| | - S. R. Allam
- Division of Nephrology, Mount Sinai School of Medicine, NY
| | - T. Montague
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Brown University Medical School, RI
| | - J. S. Bromberg
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, NY
,Department of Surgery, Mount Sinai School of Medicine, NY
,Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
| | - S. Ames
- Department of Surgery, Mount Sinai School of Medicine, NY
,Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
| | - S. Lerner
- Department of Surgery, Mount Sinai School of Medicine, NY
,Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
| | - Z. Ebcioglu
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - V. Nair
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - R. Dinavahi
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - V. Sehgal
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - P. Heeger
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - B. Schroppel
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
| | - B. Murphy
- Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, NY
,Division of Nephrology, Mount Sinai School of Medicine, NY
,Corresponding author: Barbara Murphy,
| |
Collapse
|
10
|
Abstract
Women with renal disease face increasing infertility and high-risk pregnancy as they approach end-stage renal disease due to uremia. Renal transplantation has provided these patients the ability to return to a better quality of life, and for a number of women who are of child bearing age with renal disease, it has restored their fertility and provided the opportunity to have children. But, although fertility is restored, pregnancy in these women still harbors risk to the mother, graft, and fetus. Selected patients who have stable graft function can have successful pregnancies under the supervision of a multidisciplinary team involving maternal fetal medicine specialists and transplant nephrologists. Careful observation and management are required to optimize outcome for mother and fetus.
Collapse
Affiliation(s)
- Karin M Fuchs
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
| | | | | |
Collapse
|
11
|
Affiliation(s)
- Z Ebcioglu
- Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 2003; 139:W80. [PMID: 14597479 DOI: 10.7326/0003-4819-139-9-200311040-00022-w4] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|